Risperdal, Seroquel sNDAs Submitted For Acute Mania; Other sNDAs Filed
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca and Johnson & Johnson are both pursuing acute mania indications for their atypical antipsychotic agents via supplemental NDAs submitted in December.